Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q3 EPS of ($0.68), $0.08 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $379 thousand versus the consensus estimate of $370 thousand.

Financial Guidance

Today, the Company provided operating expense guidance for the fourth quarter and full year 2019. For the fourth quarter of 2018, research and development expenses are expected to be $13 to $15 million and total operating expenses are expected to be $17 to $19 million. Total operating expenses for the fourth quarter of 2018 are expected to include approximately $1.5 million of non-cash stock compensation expense. The year-end 2018 cash balance is expected to be approximately $80 million.

For the full year 2019, research and development expenses are expected to be $54 to $58 million, and total operating expenses are expected to be $68 to $73 million. Total operating expenses for 2019 are expected to include approximately $6 million of non-cash stock compensation expens

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.